Waxman hearing probes IRB shopping, GAO sting

Share this article:
Drug companies that shop among competing institutional review boards, especially those that operate for profit, to get the most favorable clinical study results, and a Government Accountability Office “sting” operation against one of them came under scrutiny at a March hearing of the House Energy and Commerce Committee's Oversight and Investigations Subcommittee, headed by Rep. Henry Waxman (D-CA).

The GAO reported on an investigation conducted on Coast IRB after subcommittee members learned about IRB troubles during Ketek hearings in 2007, where it became known that an IRB allowed the study of Sanofi-Aventis' antibiotic to continue without examining reports about fraud it had received. 

The GAO said it created a fictitious company and and then shopped for an IRB that would approve a clinical trial with the product. Investigators then prepared an erroneous and sloppy protocol for three IRBs they had identified as not having stringent documentation requirements. 
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?